// App-Quantinova.ai

P925 : IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY)

Researchers

Presenter

  • Hans C. Lee

Principal Investigators

  • Karthik Ramasamy

  • Margaret Macro

  • Faith E. Davies

  • Rafat Abonour

  • Frits van Rhee

  • Vania T.M. Hungria

  • Noemi Puig

  • Kaili Ren

  • Dasha Cherepanov

  • Dawn Marie Stull

  • Xavier Leleu

Medical Centers

  • India

  • Takeda Pharmaceuticals U.S.A., Inc.,Lexington,Stati Uniti

  • CHU de Caen,Caen,Francia

  • Perlmutter Cancer Center, NYU Langone,New York,Estados Unidos

  • Clinica São Germano and Santa Casa Medical School,São Paulo,Brazil

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Takeda Pharmaceuticals U.S.A., Inc.,Lexington,Estados Unidos

  • Department of Clinical Haematology,Oxford University Hospitals NHS Foundation Trust,Oxford,Vereinigtes Königreich

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • Department of Haematology,Oxford University Hospitals NHS Foundation Trust,Oxford,Royaume-uni

  • Takeda Pharmaceuticals U.S.A., Inc.,Lexington,Stati Uniti

  • Takeda Development Center Americas, Inc. (TDCA),Lexington,United States

  • Indiana University School of Medicine, Indianapolis, IN

  • CHU de Caen,Caen,Francia

  • Analyses, Ltd,Brno,Tchèque, République

  • Perlmutter Cancer Center, NYU

  • Takeda Development Center Americas, Inc

  • Takeda Pharmaceuticals U.S.A., Inc.,Lexington,Verenigde Staten

  • Clinica São Germano and Santa Casa Medical School,São Paulo,Brazil

  • MD Anderson...

  • CHU Caen, Caen, France

  • Indiana University School of Medicine, Indianapolis, IN

  • CHU de Caen,Caen,Francia

  • University of Arkansas for Medical Sciences,Little Rock,Vereinigte Staaten

  • Institute of Biostatistics &amp

  • MD Anderson Cancer Center ,Houston,Verenigde Staten

  • CHU de Caen,Caen,Франция

  • Perlmutter Cancer Center NYU Langone, New York, NY

  • Analyses, Ltd,Brno,Czech

  • Department I

  • Indiana University School of Medicine,Indianapolis,Vereinigte Staaten

  • Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain

  • Perlmutter Cancer Center, NYU Langone,New York,États-unis

  • Hospital Universitari Vall

  • Pôle Ré

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Clinica São Germano and Santa Casa Medical School,São Paulo,Brazil

  • Analyses, Ltd,Brno,Tschechische Republik

  • CHU de Caen,Caen,Francia

  • Pôle Régional de Cancérologie, Department of Hematology,CHU La Milétrie-Poitiers,Poitiers,Francia

  • Analyses,

  • Indiana University School of Medicine,Indianapolis,Vereinigte Staaten

  • Indiana University School of Medicine, Indianapolis, IN

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • CHU de Caen,Caen,Francia

  • Perlmutter Cancer Center, NYU Langone,New York,Verenigde Staten

  • Clinica São Germano and Santa Casa Medical School,São Paulo,Brazil

  • Clinica São Germano and Santa Casa Medical School,São Paulo,Brazil

  • Takeda Development Center Americas, Inc. (TDCA),Lexington,United States

  • Takeda Development Center Americas, Inc. (TDCA),Lexington,United States

  • University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

  • Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain

  • Perlmutter Cancer Center, NYU Langone,New York,Verenigde Staten

  • Analyses, Ltd,Brno,Rep. Ceca

  • Takeda Pharmaceuticals USA, Inc., Cambridge, United States

  • Takeda Development Center Americas, Inc. (TDCA),Lexington,United States

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain

  • Perlmutter Cancer Center at NYU Langone Health,New York,Stati Uniti

  • Takeda Development Center Americas, Inc. (TDCA),Lexington,United States

  • Department of Haematology,Oxford University Hospitals NHS Foundation Trust,Oxford,Royaume-uni

  • Analyses, Ltd,Brno,Rep. Ceca

  • Takeda Pharmaceuticals U.S.A., Inc.,

  • Pôle Régional de Cancérologie, Department of Hematology,CHU La Milétrie-Poitiers,Poitiers,Francia

  • Takeda Pharmaceuticals U.S.A., Inc.,Lexington,Verenigde Staten

  • Pôle Régional de Cancérologie, Department of Hematology,CHU La Milétrie-Poitiers,Poitiers,Francia

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • MD Anderson Cancer Center ,Houston,Verenigde Staten

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • Clinica São Germano and Santa Casa Medical School,São Paulo,Brazil

  • Indiana University School of Medicine, Indianapolis, IN

Locations

  • United States

  • United Kingdom

  • France

  • India

  • Brazil

  • Mexico

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Ixazomib

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved